Francisco R López-Picón1,2, Anniina Snellman3,2, Olli Eskola4, Semi Helin4, Olof Solin4,5,6, Merja Haaparanta-Solin3,2, Juha O Rinne7,8. 1. Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland francisco.lopez@utu.fi. 2. MediCity Research Laboratory, University of Turku, Turku, Finland. 3. Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland. 4. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland. 5. Department of Chemistry, University of Turku, Turku, Finland. 6. Accelerator Laboratory, Åbo Akademi University, Turku, Finland. 7. Turku PET Centre, Turku University Hospital, Turku, Finland; and. 8. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
Abstract
Neuroinflammation has been associated with various neurologic diseases, including Alzheimer disease (AD). In AD, the translocator protein 18 kDa (TSPO) is overexpressed in the activated microglia that surround the β-amyloid plaques. In the current longitudinal study using a mouse model of AD, we evaluated the association between β-amyloid deposition and neuroinflammation in AD. Methods: To monitor the longitudinal changes in β-amyloid deposition and neuroinflammation, we used in vivo PET imaging and ex vivo autoradiography with Pittsburgh compound B (11C-PIB) and a TSPO tracer, flutriciclamide (18F-GE-180), in the APP23 mouse model of AD. We also applied immunohistochemistry to study β-amyloid and activated microglia in the mouse brain tissue. Results: From 17 to 26 mo of age, the mice showed robust increased binding of 11C-PIB with aging in the frontal cortex, parietotemporal cortex, hippocampus, and thalamus whereas the increase in 18F-GE-180 binding with aging was minimal in areas of early amyloidosis such as the frontal cortex and hippocampus. A clear positive correlation between β-amyloid deposition and neuroinflammation was detected with 11C-PIB and 18F-GE-180 only in the parietotemporal cortex and thalamus. Conclusion: The neuroinflammation increase detected with 18F-GE-180 is less than the increase in amyloidosis detected with 11C-PIB. Furthermore, binding of 18F-GE-180 plateaus at an earlier stage of pathogenesis whereas amyloidosis continues to increase. We suggest that TSPO can be a good marker for early pathogenesis detection but not for tracking long-term disease progression.
Neuroinflammation has been associated with various neurologic diseases, including Alzheimer disease (AD). In AD, the translocator protein 18 kDa (TSPO) is overexpressed in the activated microglia that surround the β-amyloid plaques. In the current longitudinal study using a mouse model of AD, we evaluated the association between β-amyloid deposition and neuroinflammation in AD. Methods: To monitor the longitudinal changes in β-amyloid deposition and neuroinflammation, we used in vivo PET imaging and ex vivo autoradiography with Pittsburgh compound B (11C-PIB) and a TSPO tracer, flutriciclamide (18F-GE-180), in the APP23 mouse model of AD. We also applied immunohistochemistry to study β-amyloid and activated microglia in the mouse brain tissue. Results: From 17 to 26 mo of age, the mice showed robust increased binding of 11C-PIB with aging in the frontal cortex, parietotemporal cortex, hippocampus, and thalamus whereas the increase in 18F-GE-180 binding with aging was minimal in areas of early amyloidosis such as the frontal cortex and hippocampus. A clear positive correlation between β-amyloid deposition and neuroinflammation was detected with 11C-PIB and 18F-GE-180 only in the parietotemporal cortex and thalamus. Conclusion: The neuroinflammation increase detected with 18F-GE-180 is less than the increase in amyloidosis detected with 11C-PIB. Furthermore, binding of 18F-GE-180 plateaus at an earlier stage of pathogenesis whereas amyloidosis continues to increase. We suggest that TSPO can be a good marker for early pathogenesis detection but not for tracking long-term disease progression.
Authors: Ajenthan Surendranathan; Li Su; Elijah Mak; Luca Passamonti; Young T Hong; Robert Arnold; Patricia Vázquez Rodríguez; William R Bevan-Jones; Susannah A E Brain; Tim D Fryer; Franklin I Aigbirhio; James B Rowe; John T O'Brien Journal: Brain Date: 2018-12-01 Impact factor: 13.501
Authors: Tanja Blume; Carola Focke; Finn Peters; Maximilian Deussing; Nathalie L Albert; Simon Lindner; Franz-Josef Gildehaus; Barbara von Ungern-Sternberg; Laurence Ozmen; Karlheinz Baumann; Peter Bartenstein; Axel Rominger; Jochen Herms; Matthias Brendel Journal: J Neuroinflammation Date: 2018-11-06 Impact factor: 8.322
Authors: Aisling M Chaney; Francisco R Lopez-Picon; Sophie Serrière; Rui Wang; Daniela Bochicchio; Samuel D Webb; Matthias Vandesquille; Michael K Harte; Christina Georgiadou; Catherine Lawrence; Julie Busson; Johnny Vercouillie; Clovis Tauber; Frédéric Buron; Sylvain Routier; Tristan Reekie; Anniina Snellman; Michael Kassiou; Johanna Rokka; Karen E Davies; Juha O Rinne; Dervis A Salih; Frances A Edwards; Llwyd D Orton; Stephen R Williams; Sylvie Chalon; Hervé Boutin Journal: Theranostics Date: 2021-05-03 Impact factor: 11.556
Authors: Benjamin B Tournier; Stergios Tsartsalis; Kelly Ceyzériat; Ben H Fraser; Marie-Claude Grégoire; Enikö Kövari; Philippe Millet Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Benjamin B Tournier; Stergios Tsartsalis; Kelly Ceyzériat; Valentina Garibotto; Philippe Millet Journal: Cells Date: 2020-08-21 Impact factor: 6.600